The role of alprazolam for the treatment of panic disorder in Australia

@article{Moylan2012TheRO,
  title={The role of alprazolam for the treatment of panic disorder in Australia},
  author={Steven Moylan and Francesco Giorlando and Trond Nordfj{\ae}rn and Michael Berk},
  journal={Australian \& New Zealand Journal of Psychiatry},
  year={2012},
  volume={46},
  pages={212 - 224}
}
Objective: To investigate the potential impact of increasing prescription rates of alprazolam for the treatment of panic disorder (PD) in Australia through a review of efficacy, tolerability and adverse outcome literature. Methods: Data were sourced by a literature search using MEDLINE, Embase, PsycINFO and a manual search of scientific journals to identify relevant articles. Clinical practice guidelines from the American Psychiatric Association, National Institute of Clinical Excellence, Royal… 

Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis.

This study indicates that for those who respond to an initial 8-week treatment, continuing BZDs is equivalent to antidepressants in efficacy and safety, however, the limited number of studies warranted further investigations of the long-term effectiveness and safety of BzDs.

Reconsidering benzodiazepines in the treatment of panic disorder

  • V. Starcevic
  • Medicine, Psychology
    The Australian and New Zealand journal of psychiatry
  • 2012
The role of alprazolam in the treatment of panic disorder (PD) in Australia and conclusion that it “merits renewed consideration” is examined and Moylan et al. (2012) call for further scrutiny of the underlying issues.

Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology.

The oppositional neuropharmacological interactions between chronic benzodiazepine use and antidepressant mechanism of action, which could result in reduced antidepressant efficacy and function in depression are discussed.

Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011

There was a 58.2% increase in the dispensing of psychotropic drugs in Australia from 2000 to 2011, driven by major increases in antidepressants, atypical antipsychotics and ADHD medications.

The Prevalence of Alprazolam Uses in Geriatric Patients at Dr. Mohammad Hoesin Hospital Palembang

The aim of this study was to determine the prevalence of the use of alprazolam and the indication of usage was atheroscerotic heart disease, diarrhoea and gastroenteritis of presumed infectious origin, unspecified gastritis, and thyrotoxic heart disease.

Alprazolam and wider benzodiazepine misuse in Australia – sources of supply and evidence of harms

The submission cited two references to substantiate their counterclaim, but neither of these was relevant to the issue at hand and the empirical basis of the submission was flawed.

Alprazolam Dependence – The Sting in the Tail: A Case Report

A 38-year old female seen in the emergency department after ingesting a total of 99 alprazolam tablets amounting to approximately 50 mg of alpazolam over the previous two days has a strong family history of both suicide and bipolar I disorder.

Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice

Data presented in this article support the use of benzodiazepines as treatments of choice for acute situational anxiety, chronic anxiety disorders, insomnia, alcohol withdrawal syndromes, and catatonia.

Benzodiazepine prescribing: a qualitative cross-national comparative pilot between Australia and South Africa.

[Extract] Benzodiazepines have anxiolytic, sedative, hypnotic and muscle relaxant effects and are used to treat anxiety, panic and sleep disorders. They may result in an altered mental state,

References

SHOWING 1-10 OF 134 REFERENCES

Discontinuation reactions to alprazolam in panic disorder.

The Efficacy and Safety of Alprazolam Versus Other Benzodiazepines in the Treatment of Panic Disorder

The available evidence fails to demonstrate alprazolam as superior to other benzodiazepines for the treatment of panic disorder, and statistical heterogeneity on prespecified outcomes was not eliminated by stratification on baseline anxiety level.

The development of clonazepam as a psychotropic: the massachusetts general hospital experience.

  • J. Rosenbaum
  • Medicine, Psychology
    The Journal of clinical psychiatry
  • 2004
In response to the apparent problematic pharmacokinetics of alprazolam, members of the MGH psychiatry department pursued investigation that ultimately established the antipanic efficacy of clonazepam as well as examined its effectiveness in the treatment of other disorders, such as bipolar disorder and social phobia.

Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.

An exhaustive review of the literature showed that alprazolam is significantly superior to placebo, and is at least equally effective in the relief of symptoms as tricyclic antidepressants (TCAs) such as imipramine.

A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature.

Alprazolam demonstrates efficacy for the treatment of anxiety disorders, panic disorder, and depression in the large majority of studies; for these illnesses, it appeared equal in efficacy to the active agents with which it was compared.

Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone.

The different time courses of therapeutic action of imipramine and alprazolam indicate that these drugs ameliorate panic anxiety via different mechanisms, and support the hypotheses that drugs that are efficacious in the treatment of panic disorders act by altering noradrenergic function and that drugs with primary actions on serotonin function are likely to be less effective treatments.

Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder.

The data suggest that most patients maintain benefit with long-term pharmacotherapy but that residual symptomatology may require more intensive or additional treatment strategies, and underscore the potential importance of comorbid affective and anxiety disorders as well as phobic patterns in determining long- term response to treatment.

The role of lamotrigine in the management of bipolar disorder

It would seem prudent to await greater evidence of efficacy before designating lamotrigine as first-line treatment for other bipolar indications, as the strongest evidence for its efficacy lies in the prevention of bipolar depression.

A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study.

Evidence that the serotonergic system plays a significant role in the anti-panic properties of these two SSRIs is supported, and paroxetine and citalopram show similar anti- panic properties and a good tolerability profile.
...